Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Expression of Concern: Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites
Maorong Wangab,
Ping Yaob,
Minpeng Gaoc,
Jian Jind and
Yerong Yu*ad
aDepartment of Endocrinology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. E-mail: 1100312222@vip.jiangnan.edu.cn; yerongyu@scu.cn
bDepartment of Endocrinology, Affiliated Hospital of Hubei University for Nationalities, Enshi 445000, Hubei, China
cChina Pharmaceutical University, Nanjing, Jiangsu, P. R. China
dJiangnan University, Wuxi, Jiangsu, P. R. China
First published on 22nd November 2022
Abstract
Expression of Concern for ‘Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites’ by Maorong Wang et al., RSC Adv., 2020, 10, 8044–8053, https://doi.org/10.1039/C9RA10593J.
The following article ‘Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites’ has been published in RSC Advances.
The Royal Society of Chemistry was contacted by a reader who raised concerns about scientific errors in this article, and that some of the content may have been reproduced without appropriate acknowledgement.
The authors were contacted for comment but have not responded to these concerns.
RSC Advances is publishing this Expression of Concern to alert readers to the concerns raised. An Expression of Concern will continue to be associated with the article until we receive conclusive evidence regarding the reliability of the reported data.
Laura Fisher
15/11/2022
Executive Editor, RSC Advances
| This journal is © The Royal Society of Chemistry 2022 |